Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.77 |
| ▸ | GSK3B | P49841 | 1/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.71 |
| ▸ | PIM1 | P11309 | 12/20 | 0.69 |
| ▸ | INSR | P06213 | 3/20 | 0.64 |
| ▸ | IGF1R | P08069 | 3/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623750 | 1.00 | GSK3A (0.77) | GSK3AGSK3BPIK3CGPIM1INSR | |
| SCHEMBL623748 | 1.00 | GSK3A (0.77) | GSK3AGSK3BPIK3CGPIM1INSR | |
| SCHEMBL14277836 | 0.89 | GSK3A (0.79) | GSK3AGSK3BPIK3CGPIM1INSR | |
| SCHEMBL14411129 | 0.89 | IGF1R (0.65) | GSK3AGSK3BPIK3CGPIM1INSR | |
| SCHEMBL5119787 | 0.89 | IGF1R (0.65) | GSK3AGSK3BPIK3CGPIM1INSR | |
| SCHEMBL5119790 | 0.89 | IGF1R (0.65) | GSK3AGSK3BPIK3CGPIM1INSR | |
| SCHEMBL10118546 | 0.87 | GSK3B (1.00) | GSK3AGSK3BPIM1 | |
| SCHEMBL15312944 | 0.87 | GSK3B (1.00) | GSK3AGSK3BPIM1 | |
| SCHEMBL15315398 | 0.86 | PIK3CG (0.71) | GSK3AGSK3BPIK3CGINSRIGF1R | |
| SCHEMBL3898808 | 0.86 | IGF1R (0.80) | GSK3AGSK3BPIK3CGINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20080051445-A1 | 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways | NATIONAL INSTITUTE OF IMMUNOLOGY. | 2008-02-28 | — | — | US | disclosed |
| EP-1834642-A2 | 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways | National Institute of Immunology (IN) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | GSK3A 4773/4885GSK3B 4721/4885PIK3CG 3728/4885 |
| US-20080051445-A1 | 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways | FASN, FADS2, TECR | GSK3A 4636/4885GSK3B 4629/4885PIK3CG 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.